News | August 06, 2024
SMS Pharmaceuticals reports Q1 FY25 consolidated PAT at Rs. 16.48 Cr
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
Dr. Jitendra Singh’s pioneering work on “Stress Diabetes in Kashmiri Migrants” was hailed by the World Health Organization
Ursodeoxycholic acid or ursodiol is a naturally occurring bile acid that is used dissolve cholesterol gall stones
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
Subscribe To Our Newsletter & Stay Updated
